FindTrial
Sign In

A study to determine the frequency of occurance of migraine associated vertigo and to assess its response to treatment with flunarizine

Frequency of migraine associated vertigo in patients visiting the audiovestibularclinic in a tertiary care hospital and response to specific treatment for migraine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/07/002779
Enrollment
48
Registered
2012-07-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with migrainous vertigo

Interventions

Intervention1: Flunarizine: Tab Flunarizine 10mg per oral once daily at bed time for 6 months + symptomatic treatment for acute episodes using Tab Paracetamol 1 gm per oral prn for headache and Tab Be

Sponsors

Dr Anjali Lepcha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with migrainous vertigo

Exclusion criteria

Exclusion criteria: Any patients with typical history of BPPV (and + Hallpikes test) Any patients with typical Meniereâ??s disease (AAOC criteria 1995) Any patient with past history of chronic discharging ears/history of surgery to ear/ history of permanent hearing loss. Other neurological disorders i.e. stroke, intracranial tumours Any patient who is receiving a calcium channel blocker for hypertension.

Design outcomes

Primary

MeasureTime frame
Decrease in the frequency, severity and duration of vertigo and headachesTimepoint: On follow-up after 6 months of treatment—

Secondary

MeasureTime frame
nilTimepoint: nil—

Countries

India

Contacts

Public ContactDr Anjali Lepcha

Christian Medical College Vellore

anjalilepcha@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026